» Articles » PMID: 18822124

Exhaled and Arterial Levels of Endothelin-1 Are Increased and Correlate with Pulmonary Systolic Pressure in COPD with Pulmonary Hypertension

Overview
Journal BMC Pulm Med
Publisher Biomed Central
Specialty Pulmonary Medicine
Date 2008 Sep 30
PMID 18822124
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Endothelin-1 (ET-1) and Nitric Oxide (NO) are crucial mediators for establishing pulmonary artery hypertension (PAH). We tested the hypothesis that their imbalance might also occur in COPD patients with PAH.

Methods: The aims of the study were to measure exhaled breath condensate (EBC) and circulating levels of ET-1, as well as exhaled NO (FENO) levels by, respectively, a specific enzyme immunoassay kit, and by chemiluminescence analysis in 3 groups of subjects: COPD with PAH (12), COPD only (36), and healthy individuals (15). In order to evaluate pulmonary-artery systolic pressure (PaPs), all COPD patients underwent Echo-Doppler assessment.

Results: Significantly increased exhaled and circulating levels of ET-1 were found in COPD with PAH compared to both COPD (p < 0.0001) only, and healthy controls (p < 0.0001). In COPD with PAH, linear regression analysis showed good correlation between ET-1 in EBC and PaPs (r = 0.621; p = 0.031), and between arterial levels of ET-1 and PaPs (r = 0.648; p = 0.022), while arterial levels of ET-1 inversely correlated with FEV1%, (r = -0.59, p = 0.043), and PaPs negatively correlated to PaO2 (r = -0.618; p = 0.032). Significantly reduced levels of FENO were found in COPD associated with PAH, compared to COPD only (22.92 +/- 11.38 vs.35.07 +/- 17.53 ppb; p = 0.03). Thus, we observed an imbalanced output in the breath between ET-1 and NO, as expression of pulmonary endothelium and epithelium impairment, in COPD with PAH compared to COPD only. Whether this imbalance is an early cause or result of PAH due to COPD is still unknown and deserves further investigations.

Citing Articles

Pathophysiology of Group 3 Pulmonary Hypertension Associated with Lung Diseases and/or Hypoxia.

Nakamura K, Akagi S, Ejiri K, Taya S, Saito Y, Kuroda K Int J Mol Sci. 2025; 26(2).

PMID: 39859549 PMC: 11765551. DOI: 10.3390/ijms26020835.


Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?.

Kurakula K, Smolders V, Tura-Ceide O, Jukema J, Quax P, Goumans M Biomedicines. 2021; 9(1).

PMID: 33435311 PMC: 7827874. DOI: 10.3390/biomedicines9010057.


Exhaled Nitric Oxide and Exhaled Breath Temperature as Potential Biomarkers in Patients with Pulmonary Hypertension.

Carpagnano G, Radaeli A, Lacedonia D, Correale M, Carpagnano G, Palmiotti A Biomed Res Int. 2018; 2018:7292045.

PMID: 30225263 PMC: 6129334. DOI: 10.1155/2018/7292045.


MicroRNA-338-5p modulates pulmonary hypertension-like injuries caused by SO, NO and PM co-exposure through targeting the HIF-1α/Fhl-1 pathway.

Ji X, Zhang Y, Ku T, Yun Y, Li G, Sang N Toxicol Res (Camb). 2018; 5(6):1548-1560.

PMID: 30090456 PMC: 6062392. DOI: 10.1039/c6tx00257a.


Novel relationships of markers of monocyte activation and endothelial dysfunction with pulmonary dysfunction in HIV-infected persons.

Fitzpatrick M, Nouraie M, Gingo M, Camp D, Kessinger C, Sincebaugh J AIDS. 2016; 30(9):1327-39.

PMID: 26990629 PMC: 4948184. DOI: 10.1097/QAD.0000000000001092.


References
1.
Wort S, Woods M, Warner T, Evans T, Mitchell J . Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol. 2001; 25(1):104-10. DOI: 10.1165/ajrcmb.25.1.4331. View

2.
Chalmers G, MacLeod K, Sriram S, Thomson L, McSharry C, STACK B . Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur Respir J. 1999; 13(6):1288-92. DOI: 10.1183/09031936.99.13612939. View

3.
Davie N, Haleen S, Upton P, Polak J, Yacoub M, Morrell N . ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002; 165(3):398-405. DOI: 10.1164/ajrccm.165.3.2104059. View

4.
Santos S, Peinado V, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R . Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002; 19(4):632-8. DOI: 10.1183/09031936.02.00245902. View

5.
. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View